Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bremerhaven

6 clinical trials in Bremerhaven, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bremerhaven at a glance
6
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

6 trials in Bremerhaven

Open in trial search

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Acarodermatitis

Recruiting

Study on Scabies Treatment Comparing 10% Permethrin Cream to 5% Permethrin Cream for Patients with Scabies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Permethrin
  • Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Skin ulcer

Not recruiting

Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bremerhaven

What the registry says about research in the country

01 Chronic Wound Care

Innovative research focusing on stem cell therapy for treating persistent venous leg ulcers. These trials are evaluating topical applications of specialized cell treatments for patients with therapy-resistant wounds.

  • Wound healing assessment
  • Safety monitoring
  • Therapeutic resistance

Studies aim to improve healing outcomes in patients with chronic venous ulcers that haven't responded to conventional treatments.

02 Breast Cancer Treatment

Comprehensive studies exploring advanced therapies for various types of early breast cancer, including triple-negative and hormone receptor-positive cases. Research focuses on comparing innovative treatment combinations.

  • Triple-negative breast cancer
  • HER2-positive therapy
  • Hormone receptor-positive treatment

These trials aim to improve survival rates and treatment effectiveness through personalized therapeutic approaches.

03 Personalized Cancer Therapy

Advanced research in dynamic marker-adjusted treatment protocols, comparing various therapeutic combinations for different breast cancer subtypes. Studies evaluate both neoadjuvant and adjuvant approaches.

  • Treatment response monitoring
  • Long-term survival assessment
  • Comparative therapy effectiveness

The research focuses on optimizing treatment outcomes through personalized medicine approaches.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.